Prelude Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Prelude Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41K	Sell	18,900 -3,343	-15%	-$8.3K	﹤0.01%	1137
2025 Q4	$40K	Sell	22,243 -27,548	-55%	-$56.3K	﹤0.01%	1247
2025 Q3	$111K	Sell	49,791 -6,264	-11%	-$10.2K	0.01%	1043
2025 Q2	$83K	Buy	+56,055	New	+$115K	0.01%	933
2017 Q3	–	Sell	-200	Closed	-$2K	–	1847
2017 Q2	$2K	Buy	+200	New	+$1.88K	﹤0.01%	1530
2017 Q1	–	Sell	-1,050	Closed	-$5K	–	1721
2016 Q4	$5K	Buy	+1,050	New	+$4.69K	﹤0.01%	1437
2016 Q3	–	Sell	-10	Closed	–	–	1763
2016 Q2	$0	Buy	+10	New	+$80	﹤0.01%	1697

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prelude Capital Management's PLX Position: Q1 2026 in Review

Prelude Capital Management reduced its Protalix BioTherapeutics (PLX) stake by 15% in Q1 2026, selling an estimated $8.3K and leaving 18,900 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Prelude Capital Management first reported a position in PLX in Q2 2016 and has held it in 7 quarters since. The position peaked at $111K in Q3 2025. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Prelude Capital Management held 18,900 shares of Protalix BioTherapeutics worth $41K as of Q1 2026.
Prelude Capital Management sold 3,343 Protalix BioTherapeutics shares in Q1 2026, an estimated $8.3K.
Protalix BioTherapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1137 holding.
Prelude Capital Management first reported a position in Protalix BioTherapeutics in Q2 2016 and has held it in 7 quarters since.
Prelude Capital Management's Protalix BioTherapeutics position peaked at $111K in Q3 2025.
100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.